Stay updated on CNTO1959 for Pustular/Erythrodermic Psoriasis Clinical Trial
Sign up to get notified when there's something new on the CNTO1959 for Pustular/Erythrodermic Psoriasis Clinical Trial page.

Latest updates to the CNTO1959 for Pustular/Erythrodermic Psoriasis Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has undergone significant content changes, including the removal of detailed study information regarding the efficacy and safety of CNTO1959 (Guselkumab) for treating generalized pustular psoriasis and erythrodermic psoriasis, while a new identifier and revision number have been added.SummaryDifference17%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check44 days agoChange DetectedDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to CNTO1959 for Pustular/Erythrodermic Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CNTO1959 for Pustular/Erythrodermic Psoriasis Clinical Trial page.